Related Experiment Video

Updated: Jun 1, 2026

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling
07:49

Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling

Published on: August 3, 2018

The antisense oligonucleotide trabedersen (AP 12009) for the targeted inhibition of TGF-β2

Frank Jaschinski1, Tanja Rothhammer, Piotr Jachimczak

  • 1Antisense Pharma, Josef-Engert-Str. 9, 93053 Regensburg, Germany.

Current Pharmaceutical Biotechnology
|May 31, 2011
PubMed

Insights

Trabedersen, an antisense drug targeting transforming growth factor-beta 2 (TGF-β2), shows promise for treating aggressive cancers like glioma and pancreatic carcinoma by inhibiting tumor growth and metastasis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Development

Background:

  • Malignant tumors like high-grade glioma and pancreatic carcinoma have poor prognoses.
  • Transforming growth factor-beta 2 (TGF-β2) is crucial in carcinogenesis, promoting immunosuppression and metastasis, and is overexpressed in many cancers.
  • Identifying novel molecular targets for cancer treatment is a critical research area.

Purpose of the Study:

  • To develop and evaluate trabedersen (AP 12009), an antisense phosphorothioate oligodeoxynucleotide, for specific inhibition of TGF-β2 biosynthesis.
  • To assess the efficacy and tolerability of trabedersen in preclinical and clinical settings for various advanced cancers.

Main Methods:

  • Development of trabedersen, an antisense oligodeoxynucleotide targeting TGF-β2.
  • In vitro and in vivo experiments to confirm mechanism of action, efficacy, and tolerability.
  • Clinical studies including a Phase III trial for high-grade glioma and a Phase I/II trial for pancreatic, melanoma, and colorectal cancers.

Main Results:

  • Trabedersen demonstrated its intended mode of action in preclinical studies.
  • In vitro and in vivo experiments confirmed the efficacy and tolerability of trabedersen.
  • Clinical trials are ongoing to evaluate trabedersen in patients with high-grade glioma and advanced pancreatic, metastatic melanoma, and colorectal carcinomas.

Conclusions:

  • Trabedersen is a promising therapeutic agent targeting TGF-β2 for various advanced cancers.
  • Preclinical data support the efficacy and safety of trabedersen, leading to clinical evaluation.
  • Ongoing clinical studies will further define trabedersen's role in treating aggressive malignancies.

More Related Videos

Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System11:06

Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System

Published on: July 30, 2018

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...